Tous Actualités
Suivre
Abonner Algorithme Pharma

Algorithme Pharma

Algorithme Pharma Announces a Strategic Appointment

Laval, Canada, May 12, 2010 (ots/PRNewswire)

Doug Peel, Executive
Chairman of the Board of Directors of Algorithme  Pharma, is pleased
to announce the appointment of Christopher Perkin as the  company's
President and Chief Executive Officer. Mr. Perkin will officially
join the company on May 31st.
This important appointment confirms Algorithme Pharma's
commitment to  the development of innovative strategies to better
serve its clients and  business partners. It also reflects the
company's on- going efforts to  become a world leader in clinical
research and bioanalysis.
A native of England with a solid scientific background,
Christopher Perkin is a seasoned executive and recognized leader with
more than 30  years' experience in pharmaceutical development and
business strategy.  After holding several key positions at Huntingdon
Research Center and  Beecham Pharmaceuticals, Mr. Perkin joined the
Charles River Laboratories  in Senneville, Quebec, Canada, where he
rose through the ranks to  Corporate Senior Vice President - Global
Preclinical Services with  responsibility for operations in Asia and
North America.
"Mr. Perkin is a highly talented individual with world-class
experience in our industry, and I am confident he wil create a
dynamic  environment with a renewed business focus that wil reinforce
our  industry-leading position and assure our status as a key
international  partner of pharmaceutical companies," said Doug Peel,
Executive Chairman of  the Board of Algorithme Pharma Holdings Inc.
About Algorithme Pharma
As a major global player in clinical research and bioanalysis,
Algorithme Pharma provides a wide range of services for
bioequivalence and  early stage development (Phase I/IIa) studies to
the pharmaceutical, and  biotechnology industries. In addition to its
multi-unit clinical facilities  in Canada and the United Kingdom
(more than 250 beds) and with its new  dedicated Montreal
state-of-the-art facility for Phase I clinical studies,  Algorithme
Pharma offers different services including protocol designs,  CTD/ICH
clinical reports, data management, biostatistics, quality assurance
and regulatory affairs. Successfully audited by the US FDA, Canada
TPD,  Brazil ANVISA, France AFSSAPS, UK MHRA and Austria AGES
regulatory  authorities, Algorithme Pharma conducts over 275 clinical
trials per year.     For further information: Mme Marie-Claude
Boisvert, Vice President,  Kilmer Capital Partners,
+1-(514)-973-6077; http://www.algopharm.com

Contact:

CONTACT: For further information: Mme Marie-Claude Boisvert,
VicePresident, KilmerCapital Partners,
+1-(514)-973-6077;http://www.algopharm.com

Plus de actualités: Algorithme Pharma
Plus de actualités: Algorithme Pharma